85010-93-1

Usage

Class

Alcohols

Molecular weight

242.31 g/mol

Appearance

Colorless to light yellow liquid

Solubility

Soluble in organic solvents

Uses

Synthesis of pharmaceuticals and other organic compounds

Safety precautions

May cause irritation to skin, eyes, and respiratory system

Upstream product

• 109492-77-5 methyl 2-(4-benzyloxyphenyl)-2-methylpropionic acid 
• 167762-83-6 2-(4-benzyloxyphenyl)-2-methylpropanenitrile 

Downstream Products

• 345942-08-7 C₂₃H₂₃NO₄ 
• 74773-12-9 5-{4-[2-(4-Hydroxy-phenyl)-2-methyl-propoxy]-benzyl}-thiazolidine-2,4-dione 
• 85003-12-9 2-Chloro-3-{4-[2-(4-hydroxy-phenyl)-2-methyl-propoxy]-phenyl}-propionic acid ethyl ester 

Relevant academic research and scientific papers

Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia

Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (C-30) with better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells. This in turn significantly increased the angiogenic potential of vascular endothelial and smooth muscle cells and, subsequently, induced the formation of mature, functional blood vessels in diabetic and nondiabetic HLI mice. Together, this study offers a novel, promising small-molecule-based therapeutic strategy for treating HLI.